Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Why Moderna Stock Jumped Today

By Joe Tenebruso - Jan 4, 2021 at 4:42PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The drugmaker is ramping up its coronavirus vaccine production targets.

What happened

Shares of Moderna ( MRNA 1.74% ) climbed 7% on Monday after the biotech provided investors with a COVID-19 vaccine supply update. 

So what

Moderna boosted its baseline production estimates for its coronavirus vaccine from 500 million to 600 million doses in 2021 while keeping the top end of its manufacturing projections at 1 billion. Moderna expects to make 100 million doses available in the U.S. by the end of the first quarter and a total of 200 million doses by the end of the second quarter. The drugmaker has already delivered 18 million doses to the U.S. government.

A needle is inserted in a vial that's next to other vials.

Moderna is gearing up to make more of its coronavirus vaccine in 2021. Image source: Getty Images.

"Today, our team is working as hard as they can to manufacture with high quality as many doses of the vaccine as they can," CEO Stéphane Bancel said in a letter to shareholders. "We know that each additional dose we can make will be used to protect one more life."  

Now what 

Moderna estimates that it ended 2020 with roughly $5.25 billion in cash and investments, or about four times more than it began the year with. It plans to use this cash and the cash flow from its COVID-19 vaccine to accelerate the development of its pipeline of drugs. 

"What limited our ability to do more and scale faster in the last five years was cash," Bancel said. Yet with Moderna producing cash from its commercial operations, it can now be more aggressive with its development efforts. "I believe that this will change -- in a very material way -- how we operate during fiscal 2021 and beyond, and the speed at which we scale moving forward," he said. 

Bancel will provide an update on Moderna's development pipeline during the J.P. Morgan Healthcare Conference on Jan. 11 at 4:30 p.m. EST. 

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Moderna, Inc. Stock Quote
Moderna, Inc.
$306.72 (1.74%) $5.23

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/06/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.